ArticleLeukemia2005
Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.
Article in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.The oncologist · 2012Pooled it
- Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.International journal of cancer · 2016Trial
- Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer.Molecular and clinical oncology · 2022Article
- Autoantibodies Against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017Article
- Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.Cancer medicine · 2014Article
- Biased usage of T cell receptor β-chain variable region genes of Wilms' tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors.Cancer science · 2012Article
- The bone marrow stroma in hematological neoplasms--a guilty bystander.Nature reviews. Clinical oncology · 2011Review
- Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.Cancer science · 2010Article
- Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.Experimental hematology · 2010Article
- Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.Bone marrow transplantation · 2007Article
- Article
- Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Clinical and experimental immunology · 2007Review
- An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.Cancer immunology, immunotherapy : CII · 2006Review
- Antigen-specific cellular immunotherapy of leukemia.Leukemia · 2005Review
- Wilms' tumour gene 1 (WT1) in human neoplasia.Leukemia · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Wilms' tumor gene WT1 is highly expressed in leukemias and myelodysplastic syndrome (MDS), and WT1 expression levels increase along with the disease progression in chronic myeloid leukemia and MDS. We previously reported that IgM and IgG WT1 antibodies were detected with significantly higher detection rate and antibody titers in leukemias and MDS compared to those in healthy volunteers. In this study, whether IgG humoral immune responses against WT1 protein were Th1- or Th2-type were determined by measurement of four subclasses of IgG WT1 antibody, IgG1, IgG2, IgG3, and IgG4. In leukemias and MDS, Th1-type WT1 antibodies such as IgG1, IgG2, and IgG3 were significantly increased in both detection rate and antibody titers compared to those in healthy volunteers, whereas Th2-type WT1 antibody such as IgG4 did not increase. These results showed that Th1-biased humoral immune responses against WT1 protein were generated in leukemias and MDS. These results should allow us to consider that Th1-biased cellular immune responses against WT1 protein, which was essentially needed for cancer immunotherapy targeting WT1, should be elicited in patients with hematopoietic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.